Compare AbCellera Biologics Inc (ABCL) vs Qurate Retail Inc Series A (QVCAQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Qurate Retail Inc Series A — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Qurate Retail Inc Series A trades at $0.08 (market cap $1.12M). The key difference: AbCellera Biologics Inc is far larger — about 2098.2× Qurate Retail Inc Series A's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Qurate Retail Inc Series A nearer its low. Which is the better fit depends on your goals.
| ABCL | QVCAQ | |
|---|---|---|
Market Cap | $2.35B | $1.12M |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $15.03 |
52-Week Low | $2.78 | $0.07 |
Enterprise Value | $1.99B | $4.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
QVCAQ trades at $0.109, up 37.97% in 24 hours, but technical signals are bearish with 13 sell signals on moving averages. The company reported a net loss of $2.44 billion in 2025, with negative shareholder equity of $971 million and a debt-to-asset ratio of 77.57%. Recent news highlights QVC's 40th anniversary and TikTok Shop partnership (PRNewsWire, 2026-05-28).
The outlook remains highly speculative due to persistent losses, negative equity, and high leverage. Risks include financial distress and competitive pressures, while any positive sentiment hinges on operational turnarounds. Investors should approach with caution given the fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Qurate Retail Inc Series A
Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries. Its segments include QxH, which includes QVC U.S. and HSN market and sell a wide variety of consumer products in the United States, primarily using their televised shopping programs and via the Internet through their websites and mobile applications
Read more on QVCAQ →
